EREG hFc Chimera, Human
EREG HFc Chimera, Human

The purity of EREG hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

EREG HFc Chimera, Human

EREG hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EREG hFc Chimera, Human

Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways.EGFR ligands epiregulin (EREG) and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region. As a consequence, EREG or EPGN induce less stable EGFR dimers than EGF-making them partial agonists of EGFR dimerization. Unexpectedly, this weakened dimerization elicits more sustained EGFR signaling than seen with EGF, provoking responses in breast cancer cells associated with differentiation rather than proliferation.
Z05262
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
hFc EREG (Val63-Leu108)
Accession # O14944
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 32.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 37-42 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • EREG HFc Chimera, Human
    • EREG HFc Chimera, Human

    The purity of EREG hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • EREG HFc Chimera, Human
    • EREG HFc Chimera, Human

    EREG hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways.EGFR ligands epiregulin (EREG) and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region. As a consequence, EREG or EPGN induce less stable EGFR dimers than EGF-making them partial agonists of EGFR dimerization. Unexpectedly, this weakened dimerization elicits more sustained EGFR signaling than seen with EGF, provoking responses in breast cancer cells associated with differentiation rather than proliferation.
Synonyms Proepiregulin; EPR; Epiregulin; EREG; ER

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.